The Chicago Entrepreneur

BioNTech’s stock slides 3.4% after earnings fall short of estimates amid shrinking COVID-vaccine sales

The company said it has started commercializing variant-adapted COVID vaccines for the coming season, and is also building on development efforts for other drug candidates.

Previous post FreshPet’s stock rallies after sales beat, raised outlook
Next post The Sahm Rule, carry trades and recession fear are more than the market can bear